GlassScriptPhysician profile
Kristin Hill
NPI 1235444290
$2,528.95
in general payments reported to CMS, 2019-2025
20 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.07 · 2022: $77.87 · 2023: $706 · 2024: $1,108 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,407.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.16 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $308.92 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $241.83 | 2022-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $234.75 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $202.71 | 2023-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $169.24 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $167.96 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lundbeck LLC | $157.54 | 2023-2025 | Rexulti |
| Alkermes, INC. | $108.36 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $104.31 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $91.69 | 2025 | Cobenfy |
| Zealand Pharma US, INC. | $69.14 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.72 | 2022-2024 | Caplyta |
| Tris Pharma INC | $59.31 | 2024-2025 | Dyanavel Xr |
| Lilly USA, LLC | $37.74 | 2024-2025 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.82 | 2024 | Ozempic, Rybelsus |
| Radius Health, INC. | $19.79 | 2024 | Tymlos |
| Abbott Laboratories | $18.94 | 2024 | Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $12.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.